secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001193125-22-308415
Event type: litigation
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 1.02, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics settles derivative and class actions, appoints new CEO and board
--------------------------------------------------------------------------------

- Settlement provides $14.25M cash payment to company from Mayne Pharma's D&O insurance.
- Mayne Pharma surrenders all equity and forgives certain debts owed by the company.
- Directors and officers resigned; stock options and warrants cancelled.
- Francis O'Donnell appointed Executive Chairman and CEO; new board members appointed.
- Third Amended Supply and License Agreement terminated; company retains royalty on SUBA-Itraconazole sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/d428971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-308415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer